As­cle­tis Phar­ma scraps liv­er dis­ease pro­gram; An­oth­er re­verse merg­er

Plus, news about Benev­o­len­tAI, Adap­tive Biotech­nolo­gies, Ei­sai, CNX Ther­a­peu­tics, Van­da Phar­ma­ceu­ti­cals and Nu­cle­ai:

As­cle­tis Phar­ma ends liv­er dis­ease pro­gram: The Chi­nese biotech will

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER